| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
1.61 -0.08 (-0.05%) |
10-22 16:00 |
|
Open: |
1.69 |
Pre close: |
1.69 |
Target:
|
2.83
|
|
High: |
1.76 |
Low: |
1.61 |
Resistance:
|
2.43
2.93
|
|
Volume: |
87,884 |
Market Cap: |
98M |
Support:
|
1.61
1.34
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.73
 |
MACD |
MACD(12,26):
|
-0.25 |
|
MA(20): |
2.19 |
Signal(12,26,9): |
-0.19 |
|
MA(100): |
2.92 |
Stochastic Oscillator |
%K(14,3):
|
5.30 |
|
MA(250): |
3.36 |
%D(3): |
9.26 |
|
Average Volume(K) |
3-Month: |
13720
|
52-Week |
High:
|
4.60 |
|
10-Days: |
29985 |
Low: |
1.61 |
|
RSI |
RSI(14):
|
21.67 |
Change(%): |
-58.0 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-917.5 |
Shares Out. (M) |
60.74 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-400.4 |
Shares Float (M) |
57.57 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
5.50 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
877.8 |
% Held by Institutions |
7.10 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
1483 |
|
Book Value (p.s.) |
29.760 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.05 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.44 |
P/S |
9779140608.00 |
|
Operating Margin |
-3436.07 |
Levered Free Cash Flow
(M) |
-2.57 |
P/CF |
-13.14 |
|
|
|
|
|
|
